These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 33779879)
1. Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System. Shah ED; Brenner DM; Chen VL Dig Dis Sci; 2022 Apr; 67(4):1213-1221. PubMed ID: 33779879 [TBL] [Abstract][Full Text] [Related]
2. Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation. Shah ED; Suresh S; Jou J; Chey WD; Stidham RW Am J Gastroenterol; 2020 Apr; 115(4):596-602. PubMed ID: 32022721 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. Black CJ; Burr NE; Quigley EMM; Moayyedi P; Houghton LA; Ford AC Gastroenterology; 2018 Dec; 155(6):1753-1763. PubMed ID: 30144426 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331 [TBL] [Abstract][Full Text] [Related]
5. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Videlock EJ; Cheng V; Cremonini F Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388 [TBL] [Abstract][Full Text] [Related]
6. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation. Rothstein RD; Friedenberg FK Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408 [TBL] [Abstract][Full Text] [Related]
7. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Thomas RH; Luthin DR Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701 [TBL] [Abstract][Full Text] [Related]
8. A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States. Cash BD; Lu M; Lembo A; Feuerstadt P; Nguyen L; Terasawa E; Ayyagari R; Du S; Pi S; Westermeyer B; Terreri B; Boules M; Moshiree B J Manag Care Spec Pharm; 2024 Oct; 30(10):1136-1148. PubMed ID: 39321115 [TBL] [Abstract][Full Text] [Related]
9. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome. Vazquez-Roque MI; Bouras EP Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110 [TBL] [Abstract][Full Text] [Related]
10. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. Wechsler EV; Shah ED Drugs; 2021 Nov; 81(17):1953-1968. PubMed ID: 34727333 [TBL] [Abstract][Full Text] [Related]
11. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889 [TBL] [Abstract][Full Text] [Related]
12. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807 [TBL] [Abstract][Full Text] [Related]
13. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Johnston JM; Shiff SJ; Quigley EM Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977 [TBL] [Abstract][Full Text] [Related]
14. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Atluri DK; Chandar AK; Bharucha AE; Falck-Ytter Y Neurogastroenterol Motil; 2014 Apr; 26(4):499-509. PubMed ID: 24351035 [TBL] [Abstract][Full Text] [Related]
15. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191 [TBL] [Abstract][Full Text] [Related]
17. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437 [TBL] [Abstract][Full Text] [Related]
18. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440 [TBL] [Abstract][Full Text] [Related]
19. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype. Solem CT; Patel H; Mehta S; Mody R; Macahilig C; Gao X Curr Med Res Opin; 2016 May; 32(5):899-905. PubMed ID: 26836030 [TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis. Rao SSC; Xiang X; Yan Y; Rattanakovit K; Patcharatrakul T; Parr R; Ayyala D; Sharma A Aliment Pharmacol Ther; 2020 Jun; 51(12):1332-1341. PubMed ID: 32406112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]